Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Moleculin Biotech (0K2H) Share Price & Analysis

0 Followers

0K2H Stock Chart & Stats

$5.32$0.00(0.00%)
At close: 4:30 PM GMT
$10$20$30$40Jul 27Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19
Day’s Range
$5.32 - $5.32
52-Week Range
$4.66 - $237.97
Previous Close
$5.32
Volume
N/A
Average Volume (3M)
220
Market Cap
$8.51M
Enterprise Value
$8.88M
Total Cash (Recent Filing)
$7.26M
Total Debt (Recent Filing)
$292.00K
Price to Earnings (P/E)
―
Beta
0.42
Next Earnings
Mar 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And Safety Progress

Interim clinical results provide meaningful evidence that Annamycin may improve remission outcomes in relapsed or refractory AML while avoiding a key anthracycline limitation. Continued treatment without trial modification supports the program’s development credibility over the next several quarters.

Strengthening Intellectual Property

Additional patent protection can extend exclusivity around Annamycin’s formulation technology and help preserve the commercial value of successful development. International coverage strengthens the platform’s defensibility as clinical programs advance toward potential registration and commercialization.

Low Financial Leverage

Very low debt limits fixed repayment obligations and reduces solvency pressure while the company funds clinical development. Although the equity base has eroded, the absence of significant leverage gives management more flexibility than a heavily indebted biotechnology company during ongoing development.

Bears Say

Pre-commercial Operating Model

Moleculin remains pre-commercial, so its operations currently generate no sales to offset research, clinical, and administrative costs. Persistent sizable losses leave future financial performance dependent on successful trial outcomes and eventual product approval rather than established operating revenue.

Persistent Cash Burn

Sustained negative operating and free cash flow means the company cannot currently fund development from internal operations. Continued clinical investment therefore depends on external capital, making liquidity and financing access important constraints on the pace and durability of pipeline execution.

Nasdaq Listing And Capital Access Risk

A potential Nasdaq delisting could reduce trading access and weaken the company’s ability to reach public-market investors while it finances clinical development. The hearing process may preserve trading temporarily, but there is no assurance that compliance or continued listing will be secured.

Moleculin Biotech News

0K2H FAQ

What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest share price was $4.66 and its highest was $237.97 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $8.51M.
When is Moleculin Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$28 earnings per share for the quarter, beating the consensus estimate of -$31.067 by $3.067.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 1,050,000 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$28 in its last earnings report, beating expectations of -$31.067. Following the earnings report the stock price went up 13.36%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in GB:0K2H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology